Loading clinical trials...
Loading clinical trials...
A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Conditions
Interventions
Zanubrutinib
Locations
23
United States
Banner MD Anderson Cancer Centre
Gilbert, Arizona, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
M.D. Anderson Cancer Center
Houston, Texas, United States
Concord Repatriation General Hospital
Concord, New South Wales, Australia
St George Hospital
Sydney, New South Wales, Australia
Start Date
September 4, 2014
Primary Completion Date
March 31, 2021
Completion Date
March 31, 2021
Last Updated
April 28, 2022
NCT07349849
NCT06590961
NCT05780034
NCT03050190
NCT03125577
NCT06351527
Lead Sponsor
BeiGene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions